Natural History and Management of Familial Paraganglioma Syndrome Type 1: Long-Term Data from a Large Family.

Natural History and Management of Familial Paraganglioma Syndrome Type 1: Long-Term Data from a Large Family.:

Related Articles

Natural History and Management of Familial Paraganglioma Syndrome Type 1: Long-Term Data from a Large Family.

J Clin Med. 2020 Feb 21;9(2):

Authors: Puliani G, Sesti F, Feola T, Di Leo N, Polti G, Verrico M, Modica R, Colao A, Lenzi A, Isidori AM, Cantisani V, Giannetta E, Faggiano A

Abstract

Head and neck paragangliomas are the most common clinical features of familial paraganglioma syndrome type 1 caused by succinate dehydrogenase complex subunit D (SDHD) mutation. The clinical management of this syndrome is still unclear. In this study we propose a diagnostic algorithm for SDHD mutation carriers based on our family case series and literature review. After genetic diagnosis, first evaluation should include biochemical examination and whole-body imaging. In case of lesion detection, nuclear medicine examination is required for staging and tumor characterization. The study summarizes the diagnostic accuracy of different functional imaging techniques in SDHD mutation carriers. 18F-3,4-dihydroxyphenylalanine (18F-DOPA) positron emission tomography (PET)-computed tomography (CT) is considered the gold standard. If it is not available, 123I-Metaiodobenzylguanidine (MIBG) could be used also for predicting response to radiometabolic therapy. 18F-fluoro-2-deoxy-D-glucose (18F-FDG) PET-CT has a prognostic role since high uptake identifies more aggressive cases. Finally, 68Ga-peptides PET-CT is a promising diagnostic technique, demonstrating the best diagnostic accuracy in our and in other published case series, even if this finding still needs to be confirmed in larger studies. Periodic follow-up should consist of annual biochemical and ultrasonographic screening and biannual magnetic resonance examination to identify biochemical silent tumors early.

PMID: 32098148 [PubMed]